AbClon Inc.

A174900

KR7174900001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
16,110 ^KRW	-2.95%		-3.13%	+8.70%

2023	AbClon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	AbClon Presents Non-Clon and Phase 1 Interim Results of its AT101 Novel CAR-T Therapy at the Annual 2023 AACR Conference	CI

AbClon Inc. has filed an IPO.

October 08, 2015 at 05:00 am

AbClon Inc. has filed an IPO.

Security Name: Shares
Security Type: Common Stock
PriceRange: KRW 16000 to KRW 19000

Latest news about AbClon Inc.

AbClon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
AbClon Presents Non-Clon and Phase 1 Interim Results of its AT101 Novel CAR-T Therapy at the Annual 2023 AACR Conference	17/04/23	CI
AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp.	27/09/22	CI
AbClon Inc. announced that it has received KRW 10 billion in funding from Quad Investment Management Corp.	27/07/22	CI
AbClon Inc. announced that it expects to receive KRW 11.999976975 billion in funding from Quad Investment Management Corp.	25/07/22	CI
AbClon Inc. announced that it expects to receive KRW 10 billion in funding from Quad Investment Management Corp.	25/07/22	CI
AbClon Inc. announced that it has received KRW 13.999902624 billion in funding	27/11/19	CI
AbClon Inc. announced that it expects to receive KRW 13.999902624 billion in funding	13/11/19	CI
AbClon Inc.(KOSDAQ:A174900) added to S&P Global BMI Index	18/12/17	CI
AbClon Inc. has completed an IPO in the amount of KRW 6.80741 billion.	17/09/17	CI
AbClon Inc. has filed an IPO.	18/05/17	CI
AbClon Inc. has withdrawn its IPO.	17/05/17	CI
AbClon Inc. has filed an IPO.	08/10/15	CI

AbClon Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
ABCLON INC.	+8.70%	200M
CSL LIMITED	+0.75%	92.38B
SAMSUNG BIOLOGICS CO.,LTD.	-3.03%	37.9B
BIOGEN INC.	-10.46%	33.73B
UCB	+73.83%	27.98B
BIOMARIN PHARMACEUTICAL INC.	-13.39%	15.86B
INCYTE CORPORATION	-1.08%	13.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.15%	11.67B
ALTEOGEN INC.	+169.04%	10.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.19%	10.04B

Biopharmaceuticals

AbClon Inc.

Equities

A174900

KR7174900001

Pharmaceuticals

AbClon Inc. has filed an IPO.

Latest news about AbClon Inc.

Chart AbClon Inc.

Company Profile

Income Statement Evolution

Sector Biopharmaceuticals